<DOC>
	<DOCNO>NCT02623257</DOCNO>
	<brief_summary>The study aim explore prevalence EGFR mutation assess ctDNA sample advance NSCLC , receive ≤ 1 prior systemic chemotherapy regimen .</brief_summary>
	<brief_title>EGFR Mutations ctDNA Patients With Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirm stage IIIB/IV NSCLC ; Patient receive ≤ 1 prior systemic chemotherapy regimen ; Provision blood ( plasma ) sample ctDNA test ; Patient must able comply protocol ; Prior receive ≥2 systemic chemotherapy regimens ; As judged investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) ; Histologically confirm small cell lung cancer metastatic tumor ; Patient histologic cytological diagnosis ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>circulate tumor DNA</keyword>
	<keyword>amplification refractory mutation system</keyword>
</DOC>